학술논문
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors
Document Type
article
Author
Lucia Parlati; Mehdi Sakka; Aurelia Retbi; Samir Bouam; Lamia Hassani; Jean-François Meritet; Pierre Rufat; Dominique Bonnefont-Rousselot; Rui Batista; Benoit Terris; Agnès Bellanger; Dominique Thabut; Aurore Vozy; Jean-Philippe Spano; Romain Coriat; François Goldwasser; Selim Aractingi; Philippe Sogni; Stanislas Pol; Vincent Mallet; Jérôme Alexandre; Jennifer Arrondeau; Pascaline Boudou-Rouquette; Sixtine De Percin; Nora Kramkimel; Olivier Huillard; Jeanne Chapron; Benedicte Deau-Fischer; Marie-Laure Brandely-Piat; Diane Damotte; Audrey Lupo; Marco Alifano; Marion Corouge; Clémence Hollande; Hélène Fontaine; Lorianne Lair Mehiri; Anaïs Vallet Pichard; Patrick Tilleul
Source
JHEP Reports, Vol 5, Iss 12, Pp 100880- (2023)
Subject
Language
English
ISSN
2589-5559
Abstract
Background & Aims: There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). Methods: In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy. For all ICI patients experiencing grade 3/4 liver injury, we conducted a causality assessment using the RUCAM method and examined patient outcomes. Results: Among 952 patients (median [IQR] age 66 [57–73] years, 64% males) who were treated with ICI between January 1, 2015, and December 31, 2019, a total of 86 (9%) progressed to grade 3/4 liver injury, and liver failure was not observed. Anti-PD-(L)1/anti-CTLA-4 antibodies combinations (adjusted hazard ratio 3.36 [95% CI: 1.67–6.79]; p